Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Erik Knudsen

TitleAssociate Teaching Professor
InstitutionUniversity of Colorado Boulder
DepartmentAero-Aerospace Engineering Sci

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Knudsen ES, Witkiewicz AK, Kabraji S. The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond. Nat Rev Drug Discov. 2026 Apr 27. PMID: 42045425.
      View in: PubMed
    2. Dommer AP, Kyne R, Wang J, O'Connor TN, Koren A, Knudsen ES, Witkiewicz AK. Cyclin E modulates vulnerability to CDC7 kinase inhibition. Oncogenesis. 2026 Apr 24. PMID: 42031714.
      View in: PubMed
    3. Denkert C, Rachakonda S, Pehl A, Marmé F, Martin M, Karn T, Untch M, Bonnefoi H, Kim SB, Hirmas N, Bear H, Witkiewicz AK, Im SA, DeMichele A, Van't Veer L, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff C, Kelly CM, Reimer T, Olivé MM, Knudsen ES, van Mackelenbergh M, Rojo F, Frickel N, Fasching PA, Teply-Szymanski J, Toi M, Rugo HS, Gnant M, Makris A, Felder B, Nekljudova V, Loibl S. Clinical and Molecular Evaluation of HER2-Low and HER2-Ultralow Breast Cancer in the Penelope-B Clinical Trial Cohort. Mod Pathol. 2026 Apr 21; 39(6):101006. PMID: 42025846.
      View in: PubMed
    4. O'Connor TN, Schultz E, Horowitz M, Alexander MH, Fountzilas C, Cherkassky L, Onel K, Knudsen ES, Witkiewicz AK. Increasing Use of Germline Genetic Testing in Pancreatic Ductal Adenocarcinoma and Relationship to Clinical Outcome: A Single-Institution Study. JCO Precis Oncol. 2026 Apr; 10(4):e2501088. PMID: 41990298.
      View in: PubMed
    5. Kumarasamy V, Wang J, Yau E, Abel EV, Witkiewicz AK, Knudsen ES. Targeting Distinct Cell Cycle Nodes Overcomes KRAS/RAS Inhibitor Resistance. bioRxiv. 2026 Mar 12. PMID: 41959066.
      View in: PubMed
    6. Fountzilas C, Rosario S, Witkiewicz AK, Withers HG, Bajor DL, Mukherjee S, Saltzman J, Maguire O, Minderman H, Chatley S, Tarquini ML, Whitworth A, Jurcevic J, Hsiao HH, Knudsen ES, Muhitch JB, Abrams SI, Kalinski P, Segal BH, Bakin A, Yuan G, Wang C, Attwood K, Iyer R, Boland PM. TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab. Int J Cancer. 2026 Jun 15; 158(12):3300-3311. PMID: 41793309.
      View in: PubMed
    7. Kong T, Mabry A, Highkin M, Wang AZ, Hoog J, Guo Z, Gonzales-Gonzales A, Thomas S, Song Y, Gao F, Opyrchal M, Peterson L, Ademuyiwa F, Margenthaler J, Aft R, Glover-Collins K, Nehring L, Tao Y, Sanati S, Hagemann IS, Boulos F, Holt M, Ding L, Zhu W, Oh ST, Wang J, Witkiewicz AK, Knudsen ES, Bose R, Weber JD, Goetz M, Northfelt D, Luo J, Ma CX. Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial. Nat Commun. 2026 Jan 27; 17(1):949. PMID: 41593097.
      View in: PubMed
    8. O'Connor TN, Schultz E, Kabraji S, Levine E, Williams AJ, Knudsen ES, Witkiewicz AK. Real-World Plasma Thymidine Kinase Activity in High-Risk and Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Treated With Cyclin-Dependent Kinase 4/6 Inhibitors. JCO Precis Oncol. 2026 Jan; 10:e2500346. PMID: 41576303.
      View in: PubMed
    9. Wan Y, Wang J, O'Connor TN, Kumarasamy V, Sanidas I, Abrams SI, Witkiewicz AK, Knudsen ES. Intrinsic RB activation induces tumoral and stromal anti-tumor responses that limit triple-negative breast cancer. NPJ Breast Cancer. 2025 Dec 01; 11(1):134. PMID: 41326426.
      View in: PubMed
    10. Sine CC, Watts LP, Fernandez B, Marikar N, Wang J, Knudsen ES, Witkiewicz AK, Spencer SL. p16 expression confers sensitivity to CDK2 inhibitors in cyclin E1-driven ovarian cancers. Sci Signal. 2025 Nov 25; 18(914):eadv0415. PMID: 41289358.
      View in: PubMed
    11. Witkiewicz AK, Kaligotla Venkata SA, Knudsen ES, Kumarasamy V. RB loss sensitizes triple-negative breast cancer to apoptosis induced by cellular stress. Cell Death Discov. 2025 Nov 24; 11(1):543. PMID: 41285729.
      View in: PubMed
    12. Humphrey KS, Crawford KJ, Muppavarapu B, Mayberry MM, Morris W, Torres E, Long MD, Wang J, Knudsen ES, Witkiewicz AK, Abel EV. HNF1A is a novel BRD4 target and critical for BET-inhibitor response in pancreatic ductal adenocarcinoma. bioRxiv. 2025 Oct 02. PMID: 41256683.
      View in: PubMed
    13. Knudsen ES, O'Connor TN, Witkiewicz AK. Cell Cycle Plasticity and Heterogeneity: An Underappreciated Feature of Cancer and Treatment Response. Cancer Heterog Plast. 2025; 2(3). PMID: 41103573.
      View in: PubMed
    14. Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Im SA, DeMichele A, Van't Veer L, Kim SB, Bear H, McCarthy N, Rhiem K, Turner N, Witkiewicz A, Rojo F, Filipits M, Martin LA, Fasching PA, Schem C, Becker K, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Loibl S. Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies. JCO Precis Oncol. 2025 Sep; 9:e2500588. PMID: 40893049.
      View in: PubMed
    15. Knudsen ES, Witkiewicz AK, Sanidas I, Rubin SM. Targeting CDK2 for cancer therapy. Cell Rep. 2025 Aug 26; 44(8):116140. PMID: 40802510.
      View in: PubMed
    16. Crawford KJ, Humphrey KS, Cortes E, Wang J, Kumarasamy V, Wan Y, Long MD, Feigin ME, Witkiewicz AK, Mann KM, Knudsen ES, Abel EV. Targeting FGFR4 abrogates HNF1A-driven metastasis in pancreatic ductal adenocarcinoma. Mol Cancer. 2025 Jul 29; 24(1):208. PMID: 40731412.
      View in: PubMed
    17. Tzetzo SL, Schultz E, Wang J, Rosenheck HR, Mahan S, Knudsen ES, Witkiewicz AK. Baseline cell cycle and immune profiles indicate CDK4/6 inhibitor response in metastatic HR?+?/HER2- breast cancer. NPJ Breast Cancer. 2025 Jun 12; 11(1):54. PMID: 40506447.
      View in: PubMed
    18. Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW, Jiang D, Gammon ST, Willey CD, Boutros PC, Sandulache VC, Osman AA, Myers JN, Mehla K, Singh PK, Chan KS, Gao H, Marathe H. Acquired resistance in cancer: towards targeted therapeutic strategies. Nat Rev Cancer. 2025 Aug; 25(8):613-633. PMID: 40461793.
      View in: PubMed
    19. Patel R, Fountzilas C, Horowitz M, Schultz E, Clayback KM, Knudsen ES, Witkiewicz AK, Onel K. Pancreatic adenocarcinoma in a patient with a germline RB1 pathogenic variant. Fam Cancer. 2025 May 26; 24(2):46. PMID: 40418431.
      View in: PubMed
    20. Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Im SA, DeMichele A, Van't Veer L, Kim SB, Bear H, McCarthy N, Rhiem K, Turner N, Witkiewicz A, Rojo F, Filipits M, Martin LA, Fasching PA, Schem C, Becker K, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Loibl S. BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis. JCO Precis Oncol. 2025 Apr; 9:e2400742. PMID: 40209141.
      View in: PubMed
    21. Dommer AP, Kumarasamy V, Wang J, O'Connor TN, Roti M, Mahan S, McLean K, Knudsen ES, Witkiewicz AK. Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222. Cancer Res. 2025 Apr 03; 85(7):1310-1326. PMID: 39945638.
      View in: PubMed
    22. Witkiewicz AK, Wang J, Schultz E, O'Connor TN, O'Connor T, Levine E, Knudsen ES. Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer. Oncogene. 2025 May; 44(19):1387-1399. PMID: 40011574.
      View in: PubMed
    23. Sine C, Watts L, Fernandez B, Wang J, Knudsen E, Witkiewicz A, Spencer SL. p16 expression confers sensitivity to CDK2 inhibitors. bioRxiv. 2025 Feb 15. PMID: 39990340.
      View in: PubMed
    24. Denkert C, Rachakonda S, Karn T, Weber K, Martin M, Marmé F, Untch M, Bonnefoi H, Kim SB, Seiler S, Bear HD, Witkiewicz AK, Im SA, DeMichele A, Pehl A, Van't Veer L, McCarthy N, Stiewe T, Jank P, Gelmon KA, García-Sáenz JA, Westhoff CC, Kelly CM, Reimer T, Felder B, Olivé MM, Knudsen ES, Turner N, Rojo F, Schmitt WD, Fasching PA, Teply-Szymanski J, Zhang Z, Toi M, Rugo HS, Gnant M, Makris A, Holtschmidt J, Nekljudova V, Loibl S. Dynamics of molecular heterogeneity in high-risk luminal breast cancer-From intrinsic to adaptive subtyping. Cancer Cell. 2025 Feb 10; 43(2):232-247.e4. PMID: 39933898.
      View in: PubMed
    25. Kumarasamy V, Wang J, Roti M, Wan Y, Dommer AP, Rosenheck H, Putta S, Trub A, Bisi J, Strum J, Roberts P, Rubin SM, Frangou C, McLean K, Witkiewicz AK, Knudsen ES. Discrete vulnerability to pharmacological CDK2 inhibition is governed by heterogeneity of the cancer cell cycle. Nat Commun. 2025 Feb 09; 16(1):1476. PMID: 39924553.
      View in: PubMed
    26. Crawford KJ, Humphrey KS, Cortes E, Wang J, Feigin ME, Witkiewicz AK, Knudsen ES, Abel EV. Targeting FGFR4 Abrogates HNF1A-driven Metastasis in Pancreatic Ductal Adenocarcinoma. bioRxiv. 2025 Feb 08. PMID: 39974881.
      View in: PubMed
    27. Wu J, Wang J, O'Connor TN, Tzetzo SL, Gurova KV, Knudsen ES, Witkiewicz AK. Separable Cell Cycle Arrest and Immune Response Elicited through Pharmacological CDK4/6 and MEK Inhibition in RASmut Disease Models. Mol Cancer Ther. 2024 Dec 03; 23(12):1801-1814. PMID: 39148328.
      View in: PubMed
    28. Ye J, Baer JM, Faget DV, Morikis VA, Ren Q, Melam A, Delgado AP, Luo X, Bagchi SM, Belle JI, Campos E, Friedman M, Veis DJ, Knudsen ES, Witkiewicz AK, Powers S, Longmore GD, DeNardo DG, Stewart SA. Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression. Cancer Discov. 2024 Jul 01; 14(7):1302-1323. PMID: 38683161.
      View in: PubMed
    29. O'Connor TN, Schultz E, Wang J, O'Connor T, Levine E, Knudsen ES, Witkiewicz AK. Real-World Experience among Elderly Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitor-Based Therapy. Cancers (Basel). 2024 Apr 30; 16(9). PMID: 38730702.
      View in: PubMed
    30. Kumarasamy V, Wang J, Frangou C, Wan Y, Dynka A, Rosenheck H, Dey P, Abel EV, Knudsen ES, Witkiewicz AK. The Extracellular Niche and Tumor Microenvironment Enhance KRAS Inhibitor Efficacy in Pancreatic Cancer. Cancer Res. 2024 04 01; 84(7):1115-1132. PMID: 38294344.
      View in: PubMed
    31. Knudsen ES, Witkiewicz AK, Rubin SM. Cancer takes many paths through G1/S. Trends Cell Biol. 2024 08; 34(8):636-645. PMID: 37953123.
      View in: PubMed
    32. Witkiewicz AK, Schultz E, Wang J, Hamilton D, Levine E, O'Connor T, Knudsen ES. Determinants of response to CDK4/6 inhibitors in the real-world setting. NPJ Precis Oncol. 2023 Sep 13; 7(1):90. PMID: 37704753.
      View in: PubMed
    33. Kumarasamy V, Gao Z, Zhao B, Jiang B, Rubin SM, Burgess K, Witkiewicz AK, Knudsen ES. PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies. Br J Cancer. 2023 10; 129(8):1238-1250. PMID: 37626264.
      View in: PubMed
    34. Kumarasamy V, Frangou C, Wang J, Wan Y, Dynka A, Rosenheck H, Dey P, Abel EV, Knudsen ES, Witkiewicz AK. Pharmacologically targeting KRAS G12D in PDAC models: tumor cell intrinsic and extrinsic impact. bioRxiv. 2023 Apr 20. PMID: 37162905.
      View in: PubMed
    35. Finnegan RM, Elshazly AM, Patel NH, Tyutyunyk-Massey L, Tran TH, Kumarasamy V, Knudsen ES, Gewirtz DA. The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer. Front Oncol. 2022; 12:966441. PMID: 36741704.
      View in: PubMed
    36. Langille E, Al-Zahrani KN, Ma Z, Liang M, Uuskula-Reimand L, Espin R, Teng K, Malik A, Bergholtz H, Ghamrasni SE, Afiuni-Zadeh S, Tsai R, Alvi S, Elia A, Lü Y, Oh RH, Kozma KJ, Trcka D, Narimatsu M, Liu JC, Nguyen T, Barutcu S, Loganathan SK, Bremner R, Bader GD, Egan SE, Cescon DW, Sørlie T, Wrana JL, Jackson HW, Wilson MD, Witkiewicz AK, Knudsen ES, Pujana MA, Wahl GM, Schramek D. Loss of Epigenetic Regulation Disrupts Lineage Integrity, Induces Aberrant Alveogenesis, and Promotes Breast Cancer. Cancer Discov. 2022 12 02; 12(12):2930-2953. PMID: 36108220.
      View in: PubMed
    37. Hamad SH, Montgomery SA, Simon JM, Bowman BM, Spainhower KB, Murphy RM, Knudsen ES, Fenton SE, Randell SH, Holt JR, Hayes DN, Witkiewicz AK, Oliver TG, Major MB, Weissman BE. Correction: TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene. 2022 Sep; 41(39):4485. PMID: 36002660.
      View in: PubMed
    38. Matsukawa T, Yin M, Baslan T, Chung YJ, Cao D, Bertoli R, Zhu YJ, Walker RL, Freeland A, Knudsen E, Lowe SW, Meltzer PS, Aplan PD. Mcm2 hypomorph leads to acute leukemia or hematopoietic stem cell failure, dependent on genetic context. FASEB J. 2022 09; 36(9):e22430. PMID: 35920299.
      View in: PubMed
    39. Knudsen ES, Schultz E, Hamilton D, Attwood K, Edge S, O'Connor T, Levine E, Witkiewicz AK. Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2- Breast Cancer at a Single Cancer Center. Oncologist. 2022 08 05; 27(8):646-654. PMID: 35666660.
      View in: PubMed
    40. Kumarasamy V, Nambiar R, Wang J, Rosenheck H, Witkiewicz AK, Knudsen ES. RB loss determines selective resistance and novel vulnerabilities in ER-positive breast cancer models. Oncogene. 2022 07; 41(27):3524-3538. PMID: 35676324.
      View in: PubMed
    41. Witkiewicz AK, Kumarasamy V, Sanidas I, Knudsen ES. Cancer cell cycle dystopia: heterogeneity, plasticity, and therapy. Trends Cancer. 2022 09; 8(9):711-725. PMID: 35599231.
      View in: PubMed
    42. Hamad SH, Montgomery SA, Simon JM, Bowman BM, Spainhower KB, Murphy RM, Knudsen ES, Fenton SE, Randell SH, Holt JR, Hayes DN, Witkiewicz AK, Oliver TG, Major MB, Weissman BE. TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. Oncogene. 2022 06; 41(25):3423-3432. PMID: 35577980.
      View in: PubMed
    43. Knudsen ES, Kumarasamy V, Nambiar R, Pearson JD, Vail P, Rosenheck H, Wang J, Eng K, Bremner R, Schramek D, Rubin SM, Welm AL, Witkiewicz AK. CDK/cyclin dependencies define extreme cancer cell-cycle heterogeneity and collateral vulnerabilities. Cell Rep. 2022 03 01; 38(9):110448. PMID: 35235778.
      View in: PubMed
    44. Fountzilas C, Bajor DL, Mukherjee S, Saltzman J, Witkiewicz AK, Maguire O, Minderman H, Nambiar R, Rosenheck HR, Knudsen ES, Muhitch JB, Abrams SI, Wang C, Hutson AD, Attwood K, Hicks KA, Jurcevic JA, Kalinski P, Iyer R, Boland PM. Phase Ib/II Study of Cetuximab plus Pembrolizumab in Patients with Advanced RAS Wild-Type Colorectal Cancer. Clin Cancer Res. 2021 12 15; 27(24):6726-6736. PMID: 34645646.
      View in: PubMed
    45. Pearson JD, Huang K, Pacal M, McCurdy SR, Lu S, Aubry A, Yu T, Wadosky KM, Zhang L, Wang T, Gregorieff A, Ahmad M, Dimaras H, Langille E, Cole SPC, Monnier PP, Lok BH, Tsao MS, Akeno N, Schramek D, Wikenheiser-Brokamp KA, Knudsen ES, Witkiewicz AK, Wrana JL, Goodrich DW, Bremner R. Binary pan-cancer classes with distinct vulnerabilities defined by pro- or anti-cancer YAP/TEAD activity. Cancer Cell. 2021 08 09; 39(8):1115-1134.e12. PMID: 34270926.
      View in: PubMed
    46. Witkiewicz AK, Cox D, Knudsen ES. Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2021; 12:25-27. PMID: 33884103.
      View in: PubMed
    47. Kumarasamy V, Vail P, Nambiar R, Witkiewicz AK, Knudsen ES. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition. Cancer Res. 2021 03 01; 81(5):1347-1360. PMID: 33323381.
      View in: PubMed
    48. Gandhi S, Pandey MR, Attwood K, Ji W, Witkiewicz AK, Knudsen ES, Allen C, Tario JD, Wallace PK, Cedeno CD, Levis M, Stack S, Funchain P, Drabick JJ, Bucsek MJ, Puzanov I, Mohammadpour H, Repasky EA, Ernstoff MS. Phase I Clinical Trial of Combination Propranolol and Pembrolizumab in Locally Advanced and Metastatic Melanoma: Safety, Tolerability, and Preliminary Evidence of Antitumor Activity. Clin Cancer Res. 2021 01 01; 27(1):87-95. PMID: 33127652.
      View in: PubMed
    49. Franco J, Balaji U, Freinkman E, Witkiewicz AK, Knudsen ES. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Cell Rep. 2020 Jul 07; 32(1):107793. PMID: 32640213.
      View in: PubMed
    50. Weinberg BA, Wang H, Witkiewicz AK, Marshall JL, He AR, Vail P, Knudsen ES, Pishvaian MJ. A Phase I Study of Ribociclib Plus Everolimus in Patients with Metastatic Pancreatic Adenocarcinoma Refractory to Chemotherapy. J Pancreat Cancer. 2020; 6(1):45-54. PMID: 32642630.
      View in: PubMed
    51. Roberts PJ, Kumarasamy V, Witkiewicz AK, Knudsen ES. Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows. Mol Cancer Ther. 2020 08; 19(8):1575-1588. PMID: 32546660.
      View in: PubMed
    52. Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ. Author Correction: Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2020 06; 26(6):982. PMID: 32483362.
      View in: PubMed
    53. Knudsen ES, Kumarasamy V, Chung S, Ruiz A, Vail P, Tzetzo S, Wu J, Nambiar R, Sivinski J, Chauhan SS, Seshadri M, Abrams SI, Wang J, Witkiewicz AK. Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer. Gut. 2021 01; 70(1):127-138. PMID: 32424005.
      View in: PubMed
    54. Knudsen ES, Shapiro GI, Keyomarsi K. Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. Am Soc Clin Oncol Educ Book. 2020 May; 40:115-126. PMID: 32421454.
      View in: PubMed
    55. Knudsen ES, Nambiar R, Rosario SR, Smiraglia DJ, Goodrich DW, Witkiewicz AK. Pan-cancer molecular analysis of the RB tumor suppressor pathway. Commun Biol. 2020 04 02; 3(1):158. PMID: 32242058.
      View in: PubMed
    56. Guiley KZ, Stevenson JW, Lou K, Barkovich KJ, Kumarasamy V, Wijeratne TU, Bunch KL, Tripathi S, Knudsen ES, Witkiewicz AK, Shokat KM, Rubin SM. p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition. Science. 2019 12 13; 366(6471). PMID: 31831640.
      View in: PubMed
    57. Kumarasamy V, Ruiz A, Nambiar R, Witkiewicz AK, Knudsen ES. Chemotherapy impacts on the cellular response to CDK4/6 inhibition: distinct mechanisms of interaction and efficacy in models of pancreatic cancer. Oncogene. 2020 02; 39(9):1831-1845. PMID: 31745297.
      View in: PubMed
    58. Grant AD, Vail P, Padi M, Witkiewicz AK, Knudsen ES. Interrogating Mutant Allele Expression via Customized Reference Genomes to Define Influential Cancer Mutations. Sci Rep. 2019 09 04; 9(1):12766. PMID: 31484939.
      View in: PubMed
    59. Knudsen ES, Pruitt SC, Hershberger PA, Witkiewicz AK, Goodrich DW. Cell Cycle and Beyond: Exploiting New RB1 Controlled Mechanisms for Cancer Therapy. Trends Cancer. 2019 05; 5(5):308-324. PMID: 31174843.
      View in: PubMed
    60. Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ. Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer. Nat Med. 2019 04; 25(4):628-640. PMID: 30833752.
      View in: PubMed
    61. Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL. Correction: Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res. 2019 Feb 15; 79(4):874. PMID: 30770369.
      View in: PubMed
    62. Knudsen ES, Kumarasamy V, Ruiz A, Sivinski J, Chung S, Grant A, Vail P, Chauhan SS, Jie T, Riall TS, Witkiewicz AK. Cell cycle plasticity driven by MTOR signaling: integral resistance to CDK4/6 inhibition in patient-derived models of pancreatic cancer. Oncogene. 2019 05; 38(18):3355-3370. PMID: 30696953.
      View in: PubMed
    63. Chung S, Vail P, Witkiewicz AK, Knudsen ES. Coordinately Targeting Cell-Cycle Checkpoint Functions in Integrated Models of Pancreatic Cancer. Clin Cancer Res. 2019 04 01; 25(7):2290-2304. PMID: 30538111.
      View in: PubMed
    64. Vaseva AV, Blake DR, Gilbert TSK, Ng S, Hostetter G, Azam SH, Ozkan-Dagliyan I, Gautam P, Bryant KL, Pearce KH, Herring LE, Han H, Graves LM, Witkiewicz AK, Knudsen ES, Pecot CV, Rashid N, Houghton PJ, Wennerberg K, Cox AD, Der CJ. KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. Cancer Cell. 2018 11 12; 34(5):807-822.e7. PMID: 30423298.
      View in: PubMed
    65. Knudsen ES, Zacksenhaus E. The vulnerability of RB loss in breast cancer: Targeting a void in cell cycle control. Oncotarget. 2018 Jul 24; 9(57):30940-30941. PMID: 30123416.
      View in: PubMed
    66. Mannakee BK, Balaji U, Witkiewicz AK, Gutenkunst RN, Knudsen ES. Sensitive and specific post-call filtering of genetic variants in xenograft and primary tumors. Bioinformatics. 2018 05 15; 34(10):1713-1718. PMID: 29325072.
      View in: PubMed
    67. Witkiewicz AK, Chung S, Brough R, Vail P, Franco J, Lord CJ, Knudsen ES. Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer. Cell Rep. 2018 01 30; 22(5):1185-1199. PMID: 29386107.
      View in: PubMed
    68. Adams TA, Vail PJ, Ruiz A, Mollaee M, McCue PA, Knudsen ES, Witkiewicz AK. Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer. Mod Pathol. 2018 02; 31(2):288-298. PMID: 28984302.
      View in: PubMed
    69. Knudsen ES, Witkiewicz AK. The transcriptome of CDK4/6 inhibition. Aging (Albany NY). 2017 Aug 30; 9(8):1859-1860. PMID: 28860413.
      View in: PubMed
    70. Knudsen ES, Hutcheson J, Vail P, Witkiewicz AK. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature. Oncotarget. 2017 Jul 04; 8(27):43678-43691. PMID: 28620137.
      View in: PubMed
    71. Knudsen ES, Vail P, Balaji U, Ngo H, Botros IW, Makarov V, Riaz N, Balachandran V, Leach S, Thompson DM, Chan TA, Witkiewicz AK. Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers. Clin Cancer Res. 2017 Aug 01; 23(15):4429-4440. PMID: 28348045.
      View in: PubMed
    72. Jansen VM, Bhola NE, Bauer JA, Formisano L, Lee KM, Hutchinson KE, Witkiewicz AK, Moore PD, Estrada MV, Sánchez V, Ericsson PG, Sanders ME, Pohlmann PR, Pishvaian MJ, Riddle DA, Dugger TC, Wei W, Knudsen ES, Arteaga CL. Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. Cancer Res. 2017 05 01; 77(9):2488-2499. PMID: 28249908.
      View in: PubMed
    73. Knudsen ES, Balaji U, Mannakee B, Vail P, Eslinger C, Moxom C, Mansour J, Witkiewicz AK. Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility. Gut. 2018 03; 67(3):508-520. PMID: 28073890.
      View in: PubMed
    74. Knudsen ES, Witkiewicz AK. The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends Cancer. 2017 01; 3(1):39-55. PMID: 28303264.
      View in: PubMed
    75. Knudsen ES, Balaji U, Freinkman E, McCue P, Witkiewicz AK. Unique metabolic features of pancreatic cancer stroma: relevance to the tumor compartment, prognosis, and invasive potential. Oncotarget. 2016 Nov 29; 7(48):78396-78411. PMID: 27623078.
      View in: PubMed
    76. Knudsen ES, Witkiewicz AK. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer. Oncotarget. 2016 Oct 25; 7(43):69111-69123. PMID: 27564114.
      View in: PubMed
    77. Witkiewicz AK, Balaji U, Eslinger C, McMillan E, Conway W, Posner B, Mills GB, O'Reilly EM, Knudsen ES. Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic Cancer. Cell Rep. 2016 08 16; 16(7):2017-31. PMID: 27498862.
      View in: PubMed
    78. Hutcheson J, Balaji U, Porembka MR, Wachsmann MB, McCue PA, Knudsen ES, Witkiewicz AK. Immunologic and Metabolic Features of Pancreatic Ductal Adenocarcinoma Define Prognostic Subtypes of Disease. Clin Cancer Res. 2016 07 15; 22(14):3606-17. PMID: 26858311.
      View in: PubMed
    79. Franco J, Balaji U, Freinkman E, Witkiewicz AK, Knudsen ES. Metabolic Reprogramming of Pancreatic Cancer Mediated by CDK4/6 Inhibition Elicits Unique Vulnerabilities. Cell Rep. 2016 Feb 09; 14(5):979-990. PMID: 26804906.
      View in: PubMed
    80. Knudsen ES, O'Reilly EM, Brody JR, Witkiewicz AK. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine. Gastroenterology. 2016 Jan; 150(1):48-63. PMID: 26385075.
      View in: PubMed
    81. Witkiewicz AK, Borja NA, Franco J, Brody JR, Yeo CJ, Mansour J, Choti MA, McCue P, Knudsen ES. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer. Oncotarget. 2015 Jun 30; 6(18):15788-801. PMID: 26158861.
      View in: PubMed
    82. Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, Mollaee M, Wagner KU, Koduru P, Yopp A, Choti MA, Yeo CJ, McCue P, White MA, Knudsen ES. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015 Apr 09; 6:6744. PMID: 25855536.
      View in: PubMed
    83. Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015 Feb; 14(2):130-46. PMID: 25633797.
      View in: PubMed
    84. Knudsen ES, McClendon AK, Franco J, Ertel A, Fortina P, Witkiewicz AK. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer. Cell Cycle. 2015; 14(1):109-22. PMID: 25602521.
      View in: PubMed
    85. Hutcheson J, Witkiewicz AK, Knudsen ES. The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy. Cell Cycle. 2015; 14(24):3812-9. PMID: 25714546.
      View in: PubMed
    86. Baek G, Tse YF, Hu Z, Cox D, Buboltz N, McCue P, Yeo CJ, White MA, DeBerardinis RJ, Knudsen ES, Witkiewicz AK. MCT4 defines a glycolytic subtype of pancreatic cancer with poor prognosis and unique metabolic dependencies. Cell Rep. 2014 Dec 24; 9(6):2233-49. PMID: 25497091.
      View in: PubMed
    87. Hutcheson J, Bourgo RJ, Balaji U, Ertel A, Witkiewicz AK, Knudsen ES. Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma. Hepatology. 2014 Oct; 60(4):1231-40. PMID: 24824777.
      View in: PubMed
    88. Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget. 2014 Aug 15; 5(15):6512-25. PMID: 25156567.
      View in: PubMed
    89. Witkiewicz AK, Balaji U, Knudsen ES. Systematically defining single-gene determinants of response to neoadjuvant chemotherapy reveals specific biomarkers. Clin Cancer Res. 2014 Sep 15; 20(18):4837-48. PMID: 25047707.
      View in: PubMed
    90. Witkiewicz AK, Cox D, Knudsen ES. CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models. Genes Cancer. 2014 Jul; 5(7-8):261-72. PMID: 25221644.
      View in: PubMed
    91. Witkiewicz AK, Knudsen ES. Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. Breast Cancer Res. 2014 May 07; 16(3):207. PMID: 25223380.
      View in: PubMed
    92. Reed C, Hutcheson J, Mayhew CN, Witkiewicz AK, Knudsen ES. RB tumor suppressive function in response to xenobiotic hepatocarcinogens. Am J Pathol. 2014 Jun; 184(6):1853-9. PMID: 24726645.
      View in: PubMed
    93. Witkiewicz AK, Cox DW, Rivadeneira D, Ertel AE, Fortina P, Schwartz GF, Knudsen ES. The retinoblastoma tumor suppressor pathway modulates the invasiveness of ErbB2-positive breast cancer. Oncogene. 2014 Jul 24; 33(30):3980-91. PMID: 24121271.
      View in: PubMed
    94. Knudsen ES, Dervishaj O, Kleer CG, Pajak T, Schwartz GF, Witkiewicz AK. EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer. Cell Cycle. 2013 Jul 01; 12(13):2042-50. PMID: 23759596.
      View in: PubMed
    95. Thangavel C, Boopathi E, Ertel A, Lim M, Addya S, Fortina P, Witkiewicz AK, Knudsen ES. Regulation of miR106b cluster through the RB pathway: mechanism and functional targets. Cell Cycle. 2013 Jan 01; 12(1):98-111. PMID: 23255112.
      View in: PubMed
    96. Knudsen ES, Pajak TF, Qeenan M, McClendon AK, Armon BD, Schwartz GF, Witkiewicz AK. Retinoblastoma and phosphate and tensin homolog tumor suppressors: impact on ductal carcinoma in situ progression. J Natl Cancer Inst. 2012 Dec 05; 104(23):1825-36. PMID: 23197489.
      View in: PubMed
    97. Witkiewicz AK, Ertel A, McFalls J, Valsecchi ME, Schwartz G, Knudsen ES. RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2012 Sep 15; 18(18):5110-22. PMID: 22811582.
      View in: PubMed
    98. Dean JL, McClendon AK, Hickey TE, Butler LM, Tilley WD, Witkiewicz AK, Knudsen ES. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors. Cell Cycle. 2012 Jul 15; 11(14):2756-61. PMID: 22767154.
      View in: PubMed
    99. McClendon AK, Dean JL, Rivadeneira DB, Yu JE, Reed CA, Gao E, Farber JL, Force T, Koch WJ, Knudsen ES. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 2012 Jul 15; 11(14):2747-55. PMID: 22751436.
      View in: PubMed
    100. Dean JL, McClendon AK, Knudsen ES. Modification of the DNA damage response by therapeutic CDK4/6 inhibition. J Biol Chem. 2012 Aug 17; 287(34):29075-87. PMID: 22733811.
      View in: PubMed
    101. Knudsen ES, Ertel A, Davicioni E, Kline J, Schwartz GF, Witkiewicz AK. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat. 2012 Jun; 133(3):1009-24. PMID: 22134623.
      View in: PubMed
    102. DelBove J, Rosson G, Strobeck M, Chen J, Archer TK, Wang W, Knudsen ES, Weissman BE. Identification of a core member of the SWI/SNF complex, BAF155/SMARCC1, as a human tumor suppressor gene. Epigenetics. 2011 Dec; 6(12):1444-53. PMID: 22139574.
      View in: PubMed
    103. Bourgo RJ, Thangavel C, Ertel A, Bergseid J, McClendon AK, Wilkens L, Witkiewicz AK, Wang JY, Knudsen ES. RB restricts DNA damage-initiated tumorigenesis through an LXCXE-dependent mechanism of transcriptional control. Mol Cell. 2011 Aug 19; 43(4):663-72. PMID: 21855804.
      View in: PubMed
    104. Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES. The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle. 2011 Aug 01; 10(15):2497-503. PMID: 21775818.
      View in: PubMed
    105. Witkiewicz AK, Rivadeneira DB, Ertel A, Kline J, Hyslop T, Schwartz GF, Fortina P, Knudsen ES. Association of RB/p16-pathway perturbations with DCIS recurrence: dependence on tumor versus tissue microenvironment. Am J Pathol. 2011 Sep; 179(3):1171-8. PMID: 21756866.
      View in: PubMed
    106. McClendon AK, Dean JL, Ertel A, Fu Z, Rivadeneira DB, Reed CA, Bourgo RJ, Witkiewicz A, Addya S, Mayhew CN, Grimes HL, Fortina P, Knudsen ES. RB and p53 cooperate to prevent liver tumorigenesis in response to tissue damage. Gastroenterology. 2011 Oct; 141(4):1439-50. PMID: 21704587.
      View in: PubMed
    107. Witkiewicz AK, Knudsen ES. RB pathway and therapeutic sensitivity: new insights in breast cancer and Tamoxifen therapy. Cell Cycle. 2011 May 15; 10(10):1525. PMID: 21502809.
      View in: PubMed
    108. Thangavel C, Dean JL, Ertel A, Knudsen KE, Aldaz CM, Witkiewicz AK, Clarke R, Knudsen ES. Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer. 2011 Jun; 18(3):333-45. PMID: 21367843.
      View in: PubMed
    109. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK, Gomella L, Knudsen ES, Nelson PS, Knudsen KE. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest. 2010 Dec; 120(12):4478-92. PMID: 21099110.
      View in: PubMed
    110. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, Whitaker-Menezes D, Daumer KM, Lin Z, Witkiewicz AK, Flomenberg N, Howell A, Pestell RG, Knudsen ES, Sotgia F, Lisanti MP. Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle. 2010 Aug 15; 9(16):3256-76. PMID: 20814239.
      View in: PubMed
    111. Dean JL, Thangavel C, McClendon AK, Reed CA, Knudsen ES. Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene. 2010 Jul 15; 29(28):4018-32. PMID: 20473330.
      View in: PubMed
    112. Kuwahara Y, Charboneau A, Knudsen ES, Weissman BE. Reexpression of hSNF5 in malignant rhabdoid tumor cell lines causes cell cycle arrest through a p21(CIP1/WAF1)-dependent mechanism. Cancer Res. 2010 Mar 01; 70(5):1854-65. PMID: 20179200.
      View in: PubMed
    113. Rivadeneira DB, Mayhew CN, Thangavel C, Sotillo E, Reed CA, Graña X, Knudsen ES. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Gastroenterology. 2010 May; 138(5):1920-30. PMID: 20100483.
      View in: PubMed
    114. Reed CA, Mayhew CN, McClendon AK, Yang X, Witkiewicz A, Knudsen ES. RB has a critical role in mediating the in vivo checkpoint response, mitigating secondary DNA damage and suppressing liver tumorigenesis initiated by aflatoxin B1. Oncogene. 2009 Dec 17; 28(50):4434-43. PMID: 19838213.
      View in: PubMed
    115. Millar EK, Dean JL, McNeil CM, O'Toole SA, Henshall SM, Tran T, Lin J, Quong A, Comstock CE, Witkiewicz A, Musgrove EA, Rui H, Lemarchand L, Setiawan VW, Haiman CA, Knudsen KE, Sutherland RL, Knudsen ES. Cyclin D1b protein expression in breast cancer is independent of cyclin D1a and associated with poor disease outcome. Oncogene. 2009 Apr 16; 28(15):1812-20. PMID: 19287456.
      View in: PubMed
    116. Sotgia F, Del Galdo F, Casimiro MC, Bonuccelli G, Mercier I, Whitaker-Menezes D, Daumer KM, Zhou J, Wang C, Katiyar S, Xu H, Bosco E, Quong AA, Aronow B, Witkiewicz AK, Minetti C, Frank PG, Jimenez SA, Knudsen ES, Pestell RG, Lisanti MP. Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts. Am J Pathol. 2009 Mar; 174(3):746-61. PMID: 19234134.
      View in: PubMed
    117. Sotgia F, Casimiro MC, Bonuccelli G, Liu M, Whitaker-Menezes D, Er O, Daumer KM, Mercier I, Witkiewicz AK, Minetti C, Capozza F, Gormley M, Quong AA, Rui H, Frank PG, Milliman JN, Knudsen ES, Zhou J, Wang C, Pestell RG, Lisanti MP. Loss of caveolin-3 induces a lactogenic microenvironment that is protective against mammary tumor formation. Am J Pathol. 2009 Feb; 174(2):613-29. PMID: 19164602.
      View in: PubMed
    118. Braden WA, McClendon AK, Knudsen ES. Cyclin-dependent kinase 4/6 activity is a critical determinant of pre-replication complex assembly. Oncogene. 2008 Nov 27; 27(56):7083-93. PMID: 18776921.
      View in: PubMed
    119. Knudsen ES, Knudsen KE. Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer. 2008 09; 8(9):714-24. PMID: 19143056.
      View in: PubMed
    120. Mercier I, Casimiro MC, Wang C, Rosenberg AL, Quong J, Minkeu A, Allen KG, Danilo C, Sotgia F, Bonuccelli G, Jasmin JF, Xu H, Bosco E, Aronow B, Witkiewicz A, Pestell RG, Knudsen ES, Lisanti MP. Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy. Cancer Biol Ther. 2008 Aug; 7(8):1212-25. PMID: 18458534.
      View in: PubMed
    121. Wang Y, Dean JL, Millar EK, Tran TH, McNeil CM, Burd CJ, Henshall SM, Utama FE, Witkiewicz A, Rui H, Sutherland RL, Knudsen KE, Knudsen ES. Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res. 2008 Jul 15; 68(14):5628-38. PMID: 18632615.
      View in: PubMed
    122. Zagorski WA, Knudsen ES, Reed MF. Retinoblastoma deficiency increases chemosensitivity in lung cancer. Cancer Res. 2007 Sep 01; 67(17):8264-73. PMID: 17804741.
      View in: PubMed
    123. Reed MF, Zagorski WA, Knudsen ES. RB activity alters checkpoint response and chemosensitivity in lung cancer lines. J Surg Res. 2007 Oct; 142(2):364-72. PMID: 17640669.
      View in: PubMed
    124. Markey MP, Bergseid J, Bosco EE, Stengel K, Xu H, Mayhew CN, Schwemberger SJ, Braden WA, Jiang Y, Babcock GF, Jegga AG, Aronow BJ, Reed MF, Wang JY, Knudsen ES. Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function. Oncogene. 2007 Sep 20; 26(43):6307-18. PMID: 17452985.
      View in: PubMed
    125. Braden WA, Lenihan JM, Lan Z, Luce KS, Zagorski W, Bosco E, Reed MF, Cook JG, Knudsen ES. Distinct action of the retinoblastoma pathway on the DNA replication machinery defines specific roles for cyclin-dependent kinase complexes in prereplication complex assembly and S-phase progression. Mol Cell Biol. 2006 Oct; 26(20):7667-81. PMID: 16908528.
      View in: PubMed
    126. Angus SP, Wheeler LJ, Ranmal SA, Zhang X, Markey MP, Mathews CK, Knudsen ES. Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem. 2002 Nov 15; 277(46):44376-84. PMID: 12221087.
      View in: PubMed
    127. Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. Re-expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene. 2002 Aug 08; 21(34):5193-203. PMID: 12149641.
      View in: PubMed
    128. Angus SP, Fribourg AF, Markey MP, Williams SL, Horn HF, DeGregori J, Kowalik TF, Fukasawa K, Knudsen ES. Active RB elicits late G1/S inhibition. Exp Cell Res. 2002 Jun 10; 276(2):201-13. PMID: 12027450.
      View in: PubMed
    129. Lan Z, Sever-Chroneos Z, Strobeck MW, Park CH, Baskaran R, Edelmann W, Leone G, Knudsen ES. DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2. J Biol Chem. 2002 Mar 08; 277(10):8372-81. PMID: 11726663.
      View in: PubMed
    130. Knudsen KE, Booth D, Naderi S, Sever-Chroneos Z, Fribourg AF, Hunton IC, Feramisco JR, Wang JY, Knudsen ES. RB-dependent S-phase response to DNA damage. Mol Cell Biol. 2000 Oct; 20(20):7751-63. PMID: 11003670.
      View in: PubMed
    131. Okuda M, Horn HF, Tarapore P, Tokuyama Y, Smulian AG, Chan PK, Knudsen ES, Hofmann IA, Snyder JD, Bove KE, Fukasawa K. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell. 2000 Sep 29; 103(1):127-40. PMID: 11051553.
      View in: PubMed
    132. Fribourg AF, Knudsen KE, Strobeck MW, Lindhorst CM, Knudsen ES. Differential requirements for ras and the retinoblastoma tumor suppressor protein in the androgen dependence of prostatic adenocarcinoma cells. Cell Growth Differ. 2000 Jul; 11(7):361-72. PMID: 10939590.
      View in: PubMed
    133. Knudsen KE, Fribourg AF, Strobeck MW, Blanchard JM, Knudsen ES. Cyclin A is a functional target of retinoblastoma tumor suppressor protein-mediated cell cycle arrest. J Biol Chem. 1999 Sep 24; 274(39):27632-41. PMID: 10488103.
      View in: PubMed
    134. Weber E, Ravi RK, Knudsen ES, Williams JR, Dillehay LE, Nelkin BD, Kalemkerian GP, Feramisco JR, Mabry M. Retinoic acid-mediated growth inhibition of small cell lung cancer cells is associated with reduced myc and increased p27Kip1 expression. Int J Cancer. 1999 Mar 15; 80(6):935-43. PMID: 10074929.
      View in: PubMed
    135. Knudsen ES, Buckmaster C, Chen TT, Feramisco JR, Wang JY. Inhibition of DNA synthesis by RB: effects on G1/S transition and S-phase progression. Genes Dev. 1998 Aug 01; 12(15):2278-92. PMID: 9694794.
      View in: PubMed
    136. Whitaker LL, Su H, Baskaran R, Knudsen ES, Wang JY. Growth suppression by an E2F-binding-defective retinoblastoma protein (RB): contribution from the RB C pocket. Mol Cell Biol. 1998 Jul; 18(7):4032-42. PMID: 9632788.
      View in: PubMed
    137. Knudsen ES, Wang JY. Hyperphosphorylated p107 and p130 bind to T-antigen: identification of a critical regulatory sequence present in RB but not in p107/p130. Oncogene. 1998 Apr 02; 16(13):1655-63. PMID: 9582013.
      View in: PubMed
    138. Arap W, Knudsen E, Sewell DA, Sidransky D, Wang JY, Huang HJ, Cavenee WK. Functional analysis of wild-type and malignant glioma derived CDKN2Abeta alleles: evidence for an RB-independent growth suppressive pathway. Oncogene. 1997 Oct 23; 15(17):2013-20. PMID: 9366518.
      View in: PubMed
    139. Knudsen ES, Wang JY. Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation. Mol Cell Biol. 1997 Oct; 17(10):5771-83. PMID: 9315635.
      View in: PubMed
    140. Obeyesekere MN, Knudsen ES, Wang JY, Zimmerman SO. A mathematical model of the regulation of the G1 phase of Rb+/+ and Rb-/- mouse embryonic fibroblasts and an osteosarcoma cell line. Cell Prolif. 1997 Mar-Apr; 30(3-4):171-94. PMID: 9375029.
      View in: PubMed
    141. Arap W, Knudsen ES, Wang JY, Cavenee WK, Huang HJ. Point mutations can inactivate in vitro and in vivo activities of p16(INK4a)/CDKN2A in human glioma. Oncogene. 1997 Feb 06; 14(5):603-9. PMID: 9053859.
      View in: PubMed
    142. Chen Y, Knudsen ES, Wang JY. The RB/p107/p130 phosphorylation pathway is not inhibited in rapamycin-induced G1-prolongation of NIH3T3 cells. Oncogene. 1996 Oct 17; 13(8):1765-71. PMID: 8895523.
      View in: PubMed
    143. Chen Y, Knudsen ES, Wang JY. Cells arrested in G1 by the v-Abl tyrosine kinase do not express cyclin A despite the hyperphosphorylation of RB. J Biol Chem. 1996 Aug 16; 271(33):19637-40. PMID: 8702661.
      View in: PubMed
    144. Knudsen KE, Knudsen ES, Wang JY, Subramani S. p34cdc2 kinase activity is maintained upon activation of the replication checkpoint in Schizosaccharomyces pombe. Proc Natl Acad Sci U S A. 1996 Aug 06; 93(16):8278-83. PMID: 8710861.
      View in: PubMed
    145. Knudsen ES, Wang JY. Differential regulation of retinoblastoma protein function by specific Cdk phosphorylation sites. J Biol Chem. 1996 Apr 05; 271(14):8313-20. PMID: 8626527.
      View in: PubMed
    146. Wang JY, Knudsen ES, Welch PJ. The retinoblastoma tumor suppressor protein. Adv Cancer Res. 1994; 64:25-85. PMID: 7879661.
      View in: PubMed
    Knudsen's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (482) concept(s)
    _
    Co-Authors Expand Description
    See all (3) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department

    Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)